Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CDT Equity Inc. filings document a Nasdaq-listed biopharmaceutical issuer with common stock and redeemable warrants, a Delaware corporate structure, and an R&D-focused business built around clinical assets, intellectual property and strategic investments. Current reports and proxy materials cover material agreements, Sarborg-related securities transactions, equity line arrangements, warrant issuances, resale registration obligations and Nasdaq shareholder-approval matters.
The filing record also addresses capital-structure changes such as reverse stock split amendments, voting results, director appointments, committee membership and Exchange Act reporting status, including annual-report timing notices. These disclosures describe CDT's governance framework, security-holder rights and financing tools.
CDT Equity Inc. submitted a Form 12b-25 notification that its Quarterly Report on Form 10-Q for the period ended March 31, 2026 could not be filed on time. The company says it could not, without unreasonable effort or expense, compile all financial statement information and expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date.
The filing discloses the company anticipates stockholders' equity will increase from a deficit as of December 31, 2025 and that the company will report a greater loss for the quarter versus the year‑ago period; amounts remain under review. The notification is signed by CEO Andrew Regan on May 15, 2026.
CDT Equity Inc. entered into amendments to its equity line of credit and a related senior secured convertible note. The company and its institutional investor set the gross purchase price for each regular ELOC closing, without purchaser consent, at $510,000. The note amendment allows the company to retain 90% of proceeds from any debt or equity financing, including the ELOC, while 10% must be applied to amounts due under the note. Both amendments are effective through May 31, 2026 and then cease to modify the original agreements.
Corvus Capital Ltd. and Andrew Regan filed Amendment No. 5 to their Schedule 13D on CDT Equity Inc., updating their ownership following recent share issuances and purchases. Corvus now beneficially owns 257,166 common shares, representing about 5.3% of the outstanding stock, while Dr. Regan beneficially owns 262,766 shares, or about 5.4%.
On March 24, 2026, CDT Equity issued Corvus 147,401 shares through a cashless exercise of all its Pre-Funded Warrants, after a 1-for-25 reverse stock split of its common stock. On May 13, 2026, Corvus purchased 100,000 shares in the open market at $1.90 per share for total cash consideration of $190,000, funded with cash on hand. The filing states the CDT shares were acquired for investment purposes.
CDT Equity Inc. director and CEO Dr. Regan reported indirect purchases and conversions through affiliated entities. On March 24, 2026, Corvus Capital Limited, which he controls, exercised all its pre-funded warrants via cashless exercise into 147,401 shares of Common Stock, eliminating the warrant position. On May 13, 2026, Corvus bought an additional 100,000 shares in the open market at $1.90 per share for total cash consideration of $190,000, bringing Corvus’s reported Common Stock holdings to 256,393 shares. Separate indirect holdings via Manoira Corporation total 773 shares, and Dr. Regan also holds 5,600 shares directly. All share amounts reflect a 1‑for‑25 reverse stock split effected on March 26, 2026.
CDT Equity Inc. registers 5,348,058 shares of Common Stock for resale by selling stockholders. The registration covers 925,925 shares issuable under an amended equity line of credit with Ascent Partners Fund LLC and 4,422,133 shares issued in connection with the Sarborg Limited purchase transaction. The Company states it will not receive any proceeds from sales by the selling stockholders and the shares may be sold from time to time at market, negotiated or private prices. The prospectus notes a 1-for-25 reverse stock split effective March 26, 2026 and references an ELOC capacity of $25.0 million.
CDT Equity Inc. director Olsen Ulrik K filed an initial Form 3 reporting his holdings of the company’s Common Stock. The filing shows direct ownership of 233,585 shares, establishing his baseline equity position as an insider. The filing does not reflect any new buy or sell transactions.
CDT Equity Inc. announced changes to its board leadership and membership. The company appointed Ulrik Olsen, age 50, as a director and member of the Audit, Compensation, and Nominating and Corporate Governance Committees. The board determined he meets independence requirements under Nasdaq and the Securities Exchange Act.
Olsen is based in New Zealand, where Sarborg Limited, in which CDT holds a 20% equity stake, has its principal place of business. He brings experience in commercial property, including director roles at Scarborough Group Limited since 2017 and managing director of OB Energy since 2018. He will participate in CDT’s non-employee director compensation program.
Freda Lewis-Hall resigned from the board and her committee roles for family health reasons, with no disagreement related to company operations. Chele Chiavacci Farley was appointed chairperson of the board and of the Nominating and Corporate Governance Committee, and Simon Fry was appointed chairperson of the Audit Committee.
CDT Equity Inc. is registering 5,348,058 shares of Common Stock for resale by selling stockholders. The registration covers (i) up to 925,925 shares issuable under an amended equity line of credit with Ascent Partners Fund LLC and (ii) 4,422,133 shares issued in connection with the Sarborg Limited purchase transaction (including shares issued upon cashless exercise of pre-funded warrants). The Company will not receive proceeds from resales and has an at‑the‑market style ELOC with capacity up to $25.0 million under which sales are at the Company’s discretion.
CDT Equity Inc. reports its annual overview as an early-stage, data-driven pharmaceutical developer that licenses clinical compounds from AstraZeneca and seeks to out-license them after pre-clinical and early clinical work. The company focuses on solid-form chemistry and artificial intelligence partnerships to reposition assets for autoimmune disease, idiopathic male infertility, oncology, dermatology, rare disease and animal health.
The report highlights a going concern warning, noting substantial doubt about CDT Equity’s ability to continue operating without additional funding and acknowledging potential dilution from future equity issuance. CDT Equity details multiple related-party agreements, including extensive AI and analytics work with Sarborg Limited and animal-health development with Manoira, as well as consulting and CRO arrangements to advance its pipeline while maintaining a lean, asset-light model.